Business
Lineage Cell Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results and Provide Business Update on March 5, 2026
CARLSBAD, Calif., February 26, 2026--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic, or "off the shelf", cell therapies for serious medical conditions, today announced that it will report its fourth quarter and full year 2025 financial and operating results on Thursday, March 5, 2026, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, March 5,
About this update from Lineage Cell Therapeutics, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1740,"height":360,"url":"https://media.zenfs.com/en/business-wire.com/7f880e5b5ec9b23d8c768d07099ccab3"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/RqMJD3SmeEkWSw6sFgTW_A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE5OTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/7f880e5b5ec9b23d8c768d07099ccab3","width":960,"height":199},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/1dw9XsDxwOI9HcAMRGNSXQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00OTY7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/7f880e5b5ec9b23d8c768d07099ccab3","width":1200,"height":248}},"lazy":false},{"type":"text","content":"CARLSBAD, Calif., February 26, 2026--(BUSINESS WIRE)--Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic, or "off the shelf", cell therapies for serious medical conditions, today announced that it will report its fourth quarter and full year 2025 financial and operating results on Thursday, March 5, 2026, following the close of the U.S. financial markets. Lineage management will also host a conference call and webcast on Thursday, March 5, 2026, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its fourth quarter and full year 2025 financial and operating results and to provide a business update.","length":697,"tagName":"p"},{"type":"text","content":"Conference Call and Webcast","length":27,"tagName":"p"},{"type":"text","content":"Interested parties may access the conference call on March 5, 2026, by dialing (888) 596-4144 from the U.S. and Canada and should request the "Lineage Cell Therapeutics Call". A live webcast of the conference call will be available online in the Investors section of Lineage’s website. A replay of the webcast will be available on Lineage’s website for 30 days and a telephone replay will be available through March 12, 2026, by dialing (800) 770-2030 from the U.S. and Canada and entering conference ID number 3958367.","length":529,"tagName":"p"},{"type":"text","content":"About Lineage Cell Therapeutics, Inc.","length":37,"tagName":"p"},{"type":"text","content":"Lineage Cell Therapeutics is a clinical-stage biotechnology company developing novel allogeneic, or "off the ...